Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21 and Combination Malaria Vaccine Challenge Study
NCT02905019Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Aug 2016
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of R21/Matrix-M in malaria (9 arms), sponsored by University of Oxford. Primary endpoints: Efficacy of adjuvanted R21 and combination regimen assessed by number of completely protected individuals at 6 months and Safety of adjuvanted R21 and combination regimen assessed by frequency of adverse events at 6 months. Started Aug 2016; status: completed.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02905019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905019.